Compare IMMR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | PRLD |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 207.5M |
| IPO Year | 1999 | 2020 |
| Metric | IMMR | PRLD |
|---|---|---|
| Price | $6.12 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $4.67 |
| AVG Volume (30 Days) | ★ 308.9K | 225.6K |
| Earning Date | 02-27-2026 | 03-10-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | ★ 82.69 | 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,013,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $5.65 | $0.61 |
| 52 Week High | $8.15 | $4.19 |
| Indicator | IMMR | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 56.67 |
| Support Level | $5.77 | $1.02 |
| Resistance Level | $6.39 | $4.10 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 43.55 | 39.32 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.